By Josh Beckerman
Biohaven shares slipped after the Food and Drug Administration extended the Prescription Drug User Fee Act date for the biopharmaceutical company's troriluzole application by three months.
The stock was down 8.5%, to $17.99, after hours Wednesday and has dropped about 47% since the start of the year.
The FDA's Division of Neurology 1 also informed the New Haven, Conn., company that it plans to hold an advisory committee meeting, but no date has been scheduled. The FDA didn't raise any new concerns in its letter.
Biohaven now expects an FDA decision in the fourth quarter.
Troriluzole is a potential treatment for spinocerebellar ataxia, a group of inherited neurodegenerative disorders.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 14, 2025 19:10 ET (23:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.